Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries

• Published in: Journal of viral hepatitis 2014-10, Vol.21 (10), p.e129-e134
• Main Authors: Rizzetto, M., Grotzinger, K., Theodore, D., Demuth, D., Irving, W. L., Manns, M., Roughley, A., Forssen, U. M.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; antiviral therapy; Europe; Female; hepatitis C; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Humans; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; thrombocytopaenia; Thrombocytopenia; Withholding Treatment - utilization; Young Adult
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.12256

Summary Antiviral therapy has been shown to reduce the risk of disease progression, liver damage and death in patients with chronic hepatitis C virus (HCV) infection. While interferon labels recommend that patients with platelet counts below 50 × 103/μL not receive interferon‐based therapy, it is unknown to what extent thrombocytopaenia influences treatment decisions in practice. This study profiles the reasons for withholding antiviral treatment in HCV patients with thrombocytopaenia in five European countries. Medical records of 466 patients who had HCV infection and thrombocytopaenia (platelet count 60 years (10.9%). The reasons for lack of treatment varied among countries, with thrombocytopaenia as a reason being more common in Italy (10.9%) and Spain (20.0%), and less common in France, Germany and the UK (3.2–7.1%). Overall, thrombocytopaenia was reported as the only reason for withholding treatment in 4.9% of untreated patients. This study demonstrates that thrombocytopaenia is one of many factors, indicative of the poor clinical state of the patient, that contributes to withholding antiviral treatment. In 4.9% of untreated patients, thrombocytopaenia can be considered as a modifiable factor to enable more HCV patients to receive guideline‐recommended therapy and thus improved clinical outcomes.